Research Analysts Set Expectations for ALLR Q3 Earnings

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Analysts at Ascendiant Capital Markets raised their Q3 2026 EPS estimates for shares of Allarity Therapeutics in a research note issued to investors on Tuesday, September 15th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will earn ($0.21) per share for the quarter, up from their prior forecast of ($0.25). Ascendiant Capital Markets has a “Buy” rating and a $10.25 price objective on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($0.92) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.21) EPS and FY2027 earnings at ($0.86) EPS.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04.

ALLR has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research note on Saturday, May 30th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $10.25.

Allarity Therapeutics Stock Up 4.8%

Allarity Therapeutics stock opened at $1.09 on Friday. Allarity Therapeutics has a 52-week low of $0.77 and a 52-week high of $1.84. The firm has a market capitalization of $17.34 million, a price-to-earnings ratio of -1.40 and a beta of 0.56. The firm has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.33.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc is a clinical-stage biotechnology company focused on developing personalized cancer treatments. The company uses its Drug Response Predictor (DRP) technology to analyze tumor biology and identify patients who may be more likely to respond to specific therapies.

Allarity’s development programs have included dovitinib, an oral multikinase inhibitor investigated for use in advanced cancers, as well as other oncology candidates and drug-specific DRP companion diagnostics.